LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o
Tag: Business Wire
CANTON, Mass.–(BUSINESS WIRE)–This week at the MEDITECH LIVE leadership summit, healthcare organizations using MEDITECH’s Traverse Exchange interoperability network highlighted significant benefits gained since implementing the network’s new Consolidated Patient Summary. Unveiled at last year’s summit, the enhanced workflow has seen swift adoption among clinicians, providing care teams with faster access to critical patient information, reducing duplicate testing, and supporting more informed
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name o
DURHAM, N.C.–(BUSINESS WIRE)–HemoSonics LLC announced today that it will be honored during Premier’s annual Supplier Innovation Celebration at its 2026 Breakthroughs Conference and Exhibition. The Innovation Celebration recognizes groundbreaking healthcare technologies launched throughout the year and highlights how these products help improve the health of communities. “Premier’s recognition of the Quantra Systems clearance in Obstetrics reinforces our commitment to delivering rapid, actiona
LOS ANGELES–(BUSINESS WIRE)—- $NAGE #Biotech–Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date. “This agreement reflects the next stage of responsible NAD+ science,” said Rob Fried,
LONDON–(BUSINESS WIRE)– FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a tru
CHICAGO–(BUSINESS WIRE)–Hyatt Hotels Corporation (NYSE: H) today announced that Amar Lalvani has been appointed Hyatt’s first-ever Chief Creative Officer, in addition to his role as President & Creative Director of the company’s Lifestyle Group, effective immediately. Lalvani will continue to serve on Hyatt’s senior leadership team and report to Mark Hoplamazian, Hyatt’s Chairman, President and Chief Executive Officer. The appointment reflects Hyatt’s continued evolution as a more insight
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 29.09.2026 FTFX IE00BD5HBQ97 58,116.00 USD 1,664,088.65 28.634
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 29.09.2026 FDNI.LN IE00BT9PVG14 425,002.00 USD 7,311,258.06 17.203
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 29.09.2026 FDNI.LN IE00BT9PVG14 425,002.00 USD 7,311,258.06 17.203